307 related articles for article (PubMed ID: 33620275)
1. The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease.
Tamargo J; Caballero R; Delpón E
Expert Opin Pharmacother; 2021 Jul; 22(10):1319-1341. PubMed ID: 33620275
[No Abstract] [Full Text] [Related]
2. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
Takkar C; Nassar T; Qunibi W
Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
[TBL] [Abstract][Full Text] [Related]
4. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
[TBL] [Abstract][Full Text] [Related]
5. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF
Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
[TBL] [Abstract][Full Text] [Related]
6. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
7. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.
Epstein M; Pitt B
Expert Opin Pharmacother; 2016 Jul; 17(10):1435-48. PubMed ID: 27180623
[TBL] [Abstract][Full Text] [Related]
9. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
[TBL] [Abstract][Full Text] [Related]
10. Hyperkalemia in chronic kidney disease: a focus on potassium lowering pharmacotherapy.
Sampani E; Theodorakopoulou M; Iatridi F; Sarafidis P
Expert Opin Pharmacother; 2023; 24(16):1775-1789. PubMed ID: 37545002
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors.
De Nicola L; Ferraro PM; Montagnani A; Pontremoli R; Dentali F; Sesti G
Intern Emerg Med; 2024 Mar; 19(2):295-306. PubMed ID: 37775712
[TBL] [Abstract][Full Text] [Related]
12. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.
Silva-Cardoso J; Brito D; Frazão JM; Ferreira A; Bettencourt P; Branco P; Fonseca C
Heart Fail Rev; 2021 Jul; 26(4):891-896. PubMed ID: 33599908
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials.
Gruver J; Al-Makki A; Shepler B
J Pharm Pharm Sci; 2023; 26():11892. PubMed ID: 38173862
[TBL] [Abstract][Full Text] [Related]
14. Advances in treatment of hyperkalemia in chronic kidney disease.
Sarafidis PA; Georgianos PI; Bakris GL
Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
[TBL] [Abstract][Full Text] [Related]
15. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
16. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
Gregg LP; Navaneethan SD
Nephrol Dial Transplant; 2023 May; 38(6):1355-1365. PubMed ID: 36264349
[TBL] [Abstract][Full Text] [Related]
17. Updates on medical management of hyperkalemia.
Lopes MB; Rocha PN; Pecoits-Filho R
Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):417-423. PubMed ID: 31268919
[TBL] [Abstract][Full Text] [Related]
18. Patiromer: a clinical review.
Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials.
Carvalho PEP; Veiga TMA; Lacerda H; Tofanelli MR; Gewehr DM; Nunes MCP; Simões E Silva AC
Clin Res Cardiol; 2023 Jul; 112(7):991-1002. PubMed ID: 37140823
[TBL] [Abstract][Full Text] [Related]
20. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
Rafique Z; Peacock WF; LoVecchio F; Levy PD
Expert Opin Pharmacother; 2015; 16(11):1727-34. PubMed ID: 26159448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]